Compare Stocks → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:KALANASDAQ:PTGXNASDAQ:TOCANASDAQ:URGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/AKALAKALA BIO$7.08+2.3%$7.33$5.10▼$19.35$19.94M-1.7523,692 shs2,359 shsPTGXProtagonist Therapeutics$27.15+0.1%$27.89$13.72▼$33.34$1.59B2.09669,329 shs1,018 shsTOCATocagen$0.71-1.4%$32.24$0.42▼$6.77$17.00M0.011.47 million shs10,400 shsURGNUroGen Pharma$13.27-1.3%$15.02$8.69▼$24.13$311.24M1.09326,214 shs195,643 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%KALAKALA BIO+2.31%+1.87%-7.09%+2.02%-54.06%PTGXProtagonist Therapeutics+5.12%+6.06%-3.49%+3.83%+7.37%TOCATocagen0.00%+5.95%+1.41%+21.56%-32.93%URGNUroGen Pharma-1.34%-7.85%+0.45%-28.27%+11.05%The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AKALAKALA BIO4.1255 of 5 stars3.55.00.04.42.30.80.0PTGXProtagonist Therapeutics1.6062 of 5 stars3.51.00.00.02.72.50.0TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AURGNUroGen Pharma3.9599 of 5 stars3.50.00.04.52.43.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/AKALAKALA BIO3.00Buy$18.00154.24% UpsidePTGXProtagonist Therapeutics3.00Buy$38.0039.96% UpsideTOCATocagenN/AN/AN/AN/AURGNUroGen Pharma3.00Buy$46.67251.67% UpsideCurrent Analyst RatingsLatest KALA, TOCA, URGN, BSTC, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $45.005/6/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/4/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.003/18/2024URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/15/2024URGNUroGen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $34.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81KALAKALA BIO$3.89M5.13N/AN/A$2.79 per share2.54PTGXProtagonist Therapeutics$60M26.53N/AN/A$5.84 per share4.65TOCATocagen$40K425.10N/AN/A$0.45 per share1.58URGNUroGen Pharma$82.71M3.76N/AN/A($2.78) per share-4.77Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/AKALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%8/1/2024 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/AURGNUroGen Pharma-$102.24M-$3.73N/AN/AN/A-123.61%N/A-70.48%5/13/2024 (Confirmed)Latest KALA, TOCA, URGN, BSTC, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/AURGNUroGen Pharma-$0.93N/A+$0.93N/AN/AN/A 3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A3/14/2024Q4 2023URGNUroGen Pharma-$0.67-$0.72-$0.05-$0.72$22.30 million$23.53 million 2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24KALAKALA BIO5.106.336.33PTGXProtagonist TherapeuticsN/A16.7116.71TOCATocagen1.881.151.15URGNUroGen PharmaN/A5.425.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%KALAKALA BIO24.61%PTGXProtagonist Therapeutics98.63%TOCATocagen21.42%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%KALAKALA BIO13.40%PTGXProtagonist Therapeutics5.00%TOCATocagen10.90%URGNUroGen Pharma11.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableKALAKALA BIO432.82 million2.44 millionNot OptionablePTGXProtagonist Therapeutics11258.64 million55.71 millionOptionableTOCATocagen7723.92 millionN/ANot OptionableURGNUroGen Pharma19823.45 million20.84 millionOptionableKALA, TOCA, URGN, BSTC, and PTGX HeadlinesSourceHeadlineUroGen Pharma (NASDAQ:URGN) Rating Reiterated by HC Wainwrightamericanbankingnews.com - May 8 at 1:22 AMBuy Rating Affirmed for Urogen Pharma on Strong Clinical Data and Market Potentialmarkets.businessinsider.com - May 7 at 2:28 AMUroGen Pharma (URGN) Set to Announce Earnings on Mondaymarketbeat.com - May 6 at 12:20 PMHC Wainwright Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)marketbeat.com - May 6 at 8:47 AMNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapybusinesswire.com - May 5 at 12:20 PMUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024businesswire.com - May 4 at 3:20 PMNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trialbusinesswire.com - May 4 at 11:50 AMUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024businesswire.com - May 3 at 8:00 AM125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLCmarketbeat.com - April 20 at 5:24 AMBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentationsmarkets.businessinsider.com - April 18 at 12:39 PMUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 18 at 8:23 AMUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancersbusinesswire.com - April 17 at 12:02 PMUroGen's UGN-103 advances to Phase 3 for bladder cancerinvesting.com - April 16 at 10:43 PMUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancerbusinesswire.com - April 15 at 8:00 AMUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekfinance.yahoo.com - April 14 at 1:17 PMUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Ratingmarkets.businessinsider.com - April 4 at 3:29 PMUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stockinsidertrades.com - March 22 at 6:30 AMUroGen: All Eyes On UGN-102seekingalpha.com - March 18 at 11:48 PMUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 17 at 5:45 PMUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 2:14 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)markets.businessinsider.com - March 14 at 11:32 PMUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102finanznachrichten.de - March 14 at 6:32 PMUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challengesfinance.yahoo.com - March 14 at 1:26 PMURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 14 at 1:03 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.UroGen PharmaNASDAQ:URGNUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.